Importantly, both groups exhibited comparable pCR rates when treated with NACT, aligning with previous studies (11,13,15,43-45) and contrasting sharply with the limited response rates generally seen in hormone-receptor-positive/HER2- BC (46, 47). The gene discussed is ERBB2; the disease is breast cancer.